Ssd (Silver Sulfadiazine) Patent Expiration, LOE Window & CMS Spending

Ssd (Silver Sulfadiazine) by Dr. Reddy's Laboratories: Off-Patent Uncontested (0 AB Generics), 0 AB generics, $7.0M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorDr. Reddy's Laboratories
FDA Application & PathwayN018578 (NDA)
Exclusivity / Cliff HorizonOff-Patent Uncontested (0 AB Generics)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$7.0M
2024 Medicare Part D Spend$5.2M
2024 Medicaid Spend$1.8M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel